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Aim: To evaluate the safety and efficacy of various initial strategies of loop diuretic
administration in patients with acute decompensated heart failure (ADHF) on diuresis,
renal function, electrolyte balance and clinical outcomes.
Methods: Consecutive patients admitted with ADHF were randomized into three groups -
intravenous furosemide infusion þ intravenous dopamine, intravenous furosemide bolus
in two divided doses and intravenous furosemide continuous infusion alone. At 48 h, the
treating physician could adjust the diuretic strategy. Primary endpoint was negative fluid
balance at 24 h after admission. Secondary end points were duration of hospital stay,
negative fluid balance at 48, 72, 96 h, the trend of serum electrolytes, and renal function
and 30 day clinical outcome (death and emergency department visits).
Results: Overall ninety patients (thirty in each group) were included in the study. There was
a greater diuresis in first 24 h (p ¼ 0.002) and a shorter hospital stay (p ¼ 0.023) with the
bolus group. There was no significant difference in renal function and serum sodium and
serum potassium levels. There was no difference in the number of emergency department
visits among the three groups.
Conclusion: All three modes of diuretic therapies can be practiced with no difference in
worsening of renal function and electrolyte levels. Bolus dose administration with, Shatrunjay Darshan, Seth Motisha x Lane, Byculla, Mumbai 400027, India. Tel.: þ91
m, drtan.27@gmail.com (R.A. Shah).
ociety of India. All rights reserved.
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Age (years)
Male
Diabetes
Hypertension
Coronary Artery Disease
Smoker
Alcoholic
Dyspnea
Paroxysmal nocturnal dyspnea and orthopnea
Edema
Ascitis
Antiplatelets
Statin
Angiotensin converting enzyme inhibitors
Angiotensin receptor blockers
Beta blockers
Spironolactone
Pulse (beats per minute)
Systolic BP (mmHg)
Diastolic BP (mmHg)
a Mean  2SD (standard deviation), Dopa ¼ dits rapid volume loss and shorter hospital stay might be a more effective diuretic
strategy.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Introduction
Acute decompensated heart failure (ADHF) is a common cause
for admission to intensive care units. Most of these patients
are treated with intravenous diuretics.1 Though diuretics are
the mainstay of treatment from many years, there are very
few randomized and prospective trials to guide therapy and
most of the guidelines are formulated upon opinion of ex-
perts.2,3 Not all patients with heart failure respond equally to
diuretics. The response is altered by renal impairment, drug
interactions, variations in splanchnic flow and drug metabo-
lism.4e8 Though different protocols of diuretic therapy have
been tried; there is no definite consensus as to which therapy
is preferable. Hence, we conducted a prospective, randomized
study to evaluate the efficacy of various diuretic strategies in
acute decompensated heart failure.
2. Aim
Toevaluate the safety and efficacy of various initial strategies of
loop diuretic administration in patientswith ADHF; on diuresis,
renal function, electrolyte balance and clinical outcomes.3. Material and method
This study was conducted from April 2010 to June 2012 at the
intensive cardiac care unit of Madras Medical Mission Hospi-
tal, Chennai, India.patients in the three g
Total Infusio
58.22  15.45a 5
66 (73.3%) 2
49 (54.4%) 1
53 (59%) 2
35 (39%) 1
16 (17.8%) 4
7 (7.8%) 4
80 (88.9%) 2
53 (58.9%) 1
35 (38.9%) 1
7 (7.8%) 2
68 (75.6%) 2
55 (61.1%) 1
35 (38.9%) 1
7 (7.8%) 0
39 (43.3%) 1
16 (17.8%) 6
93.88  27.18a 9
126.08  27.21a 1
77.77  16.25a 6
opamine.3.1. Inclusion criteria
 18 years old
 Patientswith prior clinical diagnosis of heart failure (HF) on
daily home use of oral loop diuretic for at least one month
 Patient identified within 24 h of hospital admission
 HF was defined by at least one symptom (dyspnea,
orthopnea, or edema) and one sign (rales on auscultation,
peripheral edema, ascitis) or pulmonary vascular conges-
tion on chest radiography
 Anticipated need for intravenous loop diuretics for at least
48 h
 Willingness to provide informed consent
 May be planned for intravenous dopamine (Dopa) infusion
for heart failure.3.2. Exclusion criteria
 Systolic BP <90 mmHg
 Serum creatinine >3.0 mg/dl at baseline or renal replace-
ment therapy
 Patient planned for a procedure requiring intravenous
contrast dye during the present admission.
Patient selection and treatment protocol e We prospec-
tively enrolled consecutive patients with ADHF admitted to
the emergency department of Madras Medical Mission,
Chennai. They were administered a bolus of intravenous
furosemide 40 mg. Then they were randomized into threeroups.
n þ Dopa (n ¼ 30) Bolus (n ¼ 30) Infusion (n ¼ 30) P value
6.07  16.6 59.27  16.46 59.32  13.41 0.653
0/(66.7%) 23/(76.7%) 23/(76.7%) 0.6
4/(46.7%) 18/(60.0%) 17/(56.7%) 0.559
0/(66.7%) 17/(56.7%) 16/(53.3%) 0.553
2/(40.0%) 10/(33.3%) 13/(43.3%) 0.719
/(13.3%) 6/(20.05%) 6/(20.0%) 0.738
/(13.3%) 1/(3.3%) 2/(6.7%) 0.338
6/(86.7%) 25/(83.3%) 29/(96.7%) 0.232
6/(53.3%) 17/(56.7%) 20/(66.7%) 0.551
2/(40.0%) 13/(43.3%) 10/(33.3%) 0.721
/(6.7%) 3/(10.0%) 2/(6.7%) 0.856
2/(73.3%) 23/(76.7%) 23/(76.7%) 0.942
6/(53.3%) 17/(56.7%) 20/(66.7%) 0.551
0/(33.3%) 13/(43.3%) 12/(40.0%) 0.721
/(0.0%) 2/(6.7%) 5/(16.7%) 0.053
6/(53.3%) 14/(46.7%) 9/(30.0%) 0.171
/(20.0%) 6/(20.0%) 4/(13.3%) 0.738
6.33  36.60 92.93  17.83 92.40  24.51 0.793
14.53  20.03 130.80  28.81 131.60  28.47 0.01
9.53  8.31 80.37  15.08 84.77  21.41 0.001
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i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 3 0 9e3 1 6 311groups, intravenous furosemide infusion 100 mg/
24 h þ intravenous dopamine 2.5 mg/kg/min, intravenous
furosemide bolus 100 mg/24 h in two divided doses and
intravenous furosemide continuous infusion 100 mg/24 h
(Intravenous furosemide 100 mg ¼ 10 ml was dissolved in
14 ml of 0.9% normal saline to form a solution of 24 ml. This
was given at the rate of 1 ml/h infusion or was given in two
divided bolus doses depending upon the treatment group). At
48 h, the treating physician could adjust the diuretic strategy
on the basis of patients’ clinical response. The study protocol
was approved by the institutional ethics committee. A written
and informed consent for study treatment and data collection
was obtained from each patient.
Data collection technique and tools e Patients’ baseline
characteristics on admission like diabetes, hypertension,
smoking and alcoholism, history of coronary artery disease
(CAD) and history of HF hospitalization in the past were
collected. Patients’ drugs which were used by him/her at
home were noted on admission (especially the home dose of
furosemide used by the patient for more than 1 month). All
previous medications of the patient were continued. On
arrival, patients’ clinical symptoms and signs of HF - dyspnea,
paroxysmal nocturnal dyspnea (PND), orthopnea, pedal
edema, ascitis, pulse, blood pressure (BP) and jugular venous
pressure (JVP) were collected. We evaluated the oxygen satu-
ration (SpO2), electrocardiogram (ECG), pulmonary congestion
on chest X-ray and left ventricular ejection fraction (LVEF).
Serial renal parameters and electrolytes were also assessed.
All patients were encouraged to pass urine in a bedside cali-
brated can and those who were not able to do so underwent
Foleys catheterization. The difference of total fluid intake and
urine output was calculated at pre specified time intervals.
Primary endpoint was negative fluid balance in each of these
three groups at 24 h after admission. Secondary end points
were duration of hospital stay, negative fluid balance at 48, 72,
96 h and the trend of serum sodium, serum potassium, blood
urea, serum creatinine in the three groups at 24, 48, 72 h, 7
days and 30 days, in hospital and 30 day clinical outcomes
(death and emergency department visits).
Data analysis e Data were collected prospectively. SPSS
version 15.0 (SPSS Inc, Chicago, Illinois, USA) software was
used for analysis. Continuous variables were summarized as
mean  standard deviation (SD) and categorical variables as
percentages. Chi-square test, Fischer’s Exact test were used.
As data failed ’Normality’ test, KruskaleWallis One Way
Analysis of Variance on Ranks, Friedman Repeated Measures
ANOVA, Wilcoxon Signed Rank test applied. All pair wise
multiple comparison procedures were done by Tukey Test.
Multiple Comparisons versus control group was done by
Dunnett’s method and HolmeSidakmethod. These tests were
applied with the help of a statistician. A p-value <0.05 was
considered statistically significant.
3.3. Results
Overall 93 patients were enrolled in the study. One patient
each expired in the infusion þ dopamine group and bolus
group during first 24 h of index hospitalization and one patient
in infusion group got discharged against medical advice
within 24 h of admission. These three patients were excluded
Fig. 1 e I/O fluid loss at various time intervals in infusion D Dopa, bolus and infusion groups.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 3 0 9e3 1 6312from analysis. The baseline clinical data are summarized in
Table 1. Majority of the patients were males (73.3%). Most of
them had high risk features such as hypertension (59%), dia-
betes (54.4%), prior history of CAD (39%), and a prior history of
hospitalization for HF (62.2%). Dyspneawas themost common
presentation (88.9%), followed by PND and orthopnea (58.9%),
pedal edema (38.9%), and ascitis (7.8%). The mean LVEF was
33%. There was no statistically significant difference between
the three groups of patients regarding demographics, risk
factors and symptoms. Admission BP was 114.53/
69.53  20.03/8.31 mmHg in the infusion þ dopamine group,
130.80/80.37  28.81/15.08 mmHg in the bolus group and
131.60/84.77  28.47/21.41 mmHg in the infusion group. The
difference was statistically significant [systolic BP (p ¼ 0.01);
diastolic BP (p ¼ 0.001)]. The difference between home dose
and dose after 48 h was statistically significant in all the three
groups (infusionþ dopaminee p¼ 0.0066, boluse p¼ 0.00134,
infusion e p ¼ 0.00007).
Table 2 shows the comparison of fluid loss at various in-
tervals between the three groups. The negative fluid balance
was statistically significant between the three groups at
0e24 h (p¼ 0.002), but not statistically significant at other time
intervals. Then we did pair wise comparison of fluid loss at
0e24 h between the three groups. This showed that the dif-
ference was statistically significant between
infusion þ dopamine versus bolus (p < 0.05), but not between
infusion þ dopamine versus infusion or bolus versus infusion
groups. Then we statistically compared the amount of fluid
loss at 0e24 h in each of the groups to the fluid loss at 24e48,
48e72, 72e96 h. The fluid loss inml in the bolus group at 0e24,
24e48, 48e72, 72e96 h was [mean  2SD (median) e
1117.15  726.70 (828); 752.93  421.62 (751); 757.67  500.25
(544); 688.56  218.72 (755)] and the difference was significant(p ¼ 0.044). The fluid loss in ml in infusion þ dopamine group
was 612.34  349.58 (481.10); 702.27  301.16 (825);
861.40  397.23 (825); 763.23  357.09 (645) and the difference
was significant (p < 0.001). The fluid loss in ml in infusion
group was 721.57  447.99 (628); 988.67  1143.49 (635);
951.70 720.35 (745); 722.52 299 (800) and the difference was
not significant (p¼ 0.692). Fig. 1 shows the trend of loss of fluid
in each group at various intervals.
The duration of hospital stay was 6.27  3.43 days in
infusion þ dopamine group, 5.03  3.33 days in bolus group
and 6.77  3.21 days in infusion group and the difference was
statistically significant (p ¼ 0.023). Pair wise comparison
showed that the difference was significant between the bolus
and infusion group (p < 0.05), but not significant between the
bolus and infusion þ dopamine or infusion and
infusion þ dopamine groups.
Tables 3e6 shows the comparison of serum sodium, serum
potassium, blood urea and serum creatinine respectively.
There was no statistically significant difference for the above
mentioned parameters at various time intervals between the
three groups (p > 0.05).
The number of emergency visits to the hospital for recur-
rent heart failure within the first month of discharge was 9
patients in infusion þ dopamine, 8 in bolus and 7 in infusion
groups (p ¼ 0.673). We had two deaths in the bolus group and
one in the infusion group during the 1 month follow up.4. Discussion
Themain findings of our study were: (1) greater diuresis in the
first 24 h and shorter hospital stay with the bolus dose, (2) no
difference in renal function, serum sodium or serum
Table 3 e Comparison of serum (S). Sodium (mEq/l) at various intervals between infusionD Dopa, bolus and infusion groups.
S. Sodium at- Infusion þ Dopa Bolus Infusion One-way ANOVA applied
Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR F-value p-value Difference is-
Baseline 133.87 3.86 134.00 5.00 133.13 7.65 135.50 10.75 131.20 8.31 132.50 5.50 1.310 0.519 Not Significant (NS)
24 h 133.40 4.41 135.00 7.00 132.10 7.00 135.00 6.50 131.20 8.76 133.00 8.00 0.174 0.917 NS
48 h 133.53 4.64 133.00 5.00 131.30 5.69 132.50 5.25 131.77 6.45 135.00 6.00 2.071 0.355 NS
72 h 132.53 4.13 132.00 5.00 131.73 5.40 133.00 5.25 131.80 4.76 133.50 5.75 0.116 0.943 NS
7 days 131.67 4.57 130.00 5.00 131.57 4.33 132.50 4.00 131.13 4.07 131.00 6.00 0.389 0.823 NS
30 days 133.33 4.45 134.00 6.00 132.63 4.62 134.00 5.50 131.73 3.85 130.00 6.00 1.034 0.360 NS
Table 4 e Comparison of serum (S). Potassium (mEq/l) at various intervals between infusionD Dopa, bolus and infusion groups.
S. Potassium at- Infusion þ Dopa Bolus Infusion One-way ANOVA applied
Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR F-value p-value Difference is-
Baseline 4.28 0.80 4.30 1.00 4.12 0.76 4.00 0.98 4.35 0.93 4.20 1.10 0.599 0.551 NS
24 h 3.99 0.73 3.90 1.00 3.89 0.51 3.90 0.95 4.22 0.95 4.10 1.43 1.576 0.213 NS
48 h 3.86 0.62 3.80 0.60 3.82 0.54 3.90 0.87 4.00 0.70 3.90 0.85 0.434 0.805 NS
72 h 3.86 0.51 3.90 0.50 3.80 0.54 3.80 0.52 4.09 0.55 3.90 0.80 2.480 0.090 NS
7 days 4.11 0.55 4.00 1.00 3.85 0.49 3.90 0.60 4.04 0.52 3.95 0.90 1.928 0.152 NS
30 days 4.19 0.42 4.20 0.60 4.01 0.50 4.00 0.40 4.01 0.39 4.00 0.53 4.968 0.083 NS
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Table 5 e Comparison of Blood Urea (mg/dl) at various intervals between infusion D Dopa, bolus and infusion groups.
Blood urea at- Infusion þ Dopa Bolus Infusion KruskaleWallis test applied
Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR Chi-square p-value Difference is-
Baseline 44.73 21.77 39.00 35.00 43.67 18.59 39.00 26.25 51.23 29.94 36.00 45.25 0.183 0.912 NS
24 h 45.87 23.03 40.00 51.00 46.60 19.99 41.00 15.00 53.53 30.97 35.00 42.00 0.494 0.781 NS
48 h 49.80 31.16 41.00 55.00 51.77 26.03 43.00 33.00 52.37 32.03 37.00 35.00 0.666 0.717 NS
72 h 49.93 26.71 46.00 25.00 55.07 27.66 49.50 36.50 51.73 32.76 35.00 31.25 1.443 0.486 NS
7 days 51.27 27.14 45.00 31.00 54.60 25.82 46.00 32.75 45.93 24.47 33.00 38.00 3.407 0.182 NS
30 days 40.67 22.09 33.00 28.00 47.80 20.41 40.00 34.25 40.30 20.16 32.00 13.75 5.293 0.071 NS
Table 6 e Comparison of S. Creatinine (mg/dl) at various intervals between Infusion D Dopa, Bolus and Infusion groups.
S. Creatinine at- Infusion þ Dopa Bolus Infusion KruskaleWallis test applied
Mean SD Median IQR Mean SD Median IQR Mean SD Median IQR Chi-square p-value Difference is-
Baseline 1.33 0.66 0.90 1.00 1.35 0.65 1.20 0.58 1.38 0.72 1.20 0.75 0.061 0.970 NS
24 h 1.33 0.66 1.00 1.10 1.34 0.64 1.10 0.55 1.34 0.66 1.05 0.63 0.266 0.875 NS
48 h 1.26 0.66 1.00 0.70 1.36 0.71 1.10 0.80 1.25 0.57 1.05 0.50 0.930 0.628 NS
72 h 1.25 0.69 0.90 0.70 1.35 0.73 1.15 0.55 1.23 0.60 1.00 0.50 1.794 0.408 NS
7 days 1.33 0.78 1.20 0.80 1.31 0.69 1.10 0.60 1.19 0.50 1.00 0.58 0.426 0.808 NS
30 days 1.19 0.63 0.90 0.60 1.30 0.57 1.20 0.45 1.15 0.50 1.00 0.50 3.958 0.138 NS
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the number of emergency department visits at one month
among the three groups.
The difference between the home dose and dose after 48 h
was statistically significant in all the three groups
(infusion þ dopamine e p ¼ 0.0066, bolus e p ¼ 0.00134,
infusion e p ¼ 0.00007). This suggests that patients admitted
with acute on-chronic HF required a higher intravenous dose
of furosemide as compared to the home dose.
Therewas a greater loss of fluid in the bolus group between
0e24 h (p ¼ 0.044) and in the infusion þ dopamine group be-
tween 48e72 h (p < 0.001). This could be because of a faster
initial diuresis in bolus group and peaking of diuretic effect in
infusion þ dopamine group between 48e72 h. Earlier studies
compared either a high versus low dose of diuretic strategy,
bolus versus infusion strategy or infusion versus
dopamine þ infusion strategy. In contrast we compared three
different strategies of the same diuretic dose. A Meta analysis
by Salvador et al9 (95%CI 93.1 to 449; p < 0.01), and studies by
Thomson et al,10 Pivac et al11 and Dormans et al12 showed
greater diuresis with continuous infusion than bolus group,
but studies by Aaser et al13 and Schuller et al14 found no dif-
ference between the diuretic effects of the two study groups.
Cotter et al15 studied intravenous low dose dopamine þ low
dose oral furosemide, intravenous low dose
dopamine þmedium dose furosemide infusion and high dose
furosemide infusion. They found similar urine output in all
the three groups. In DOSE trial,16 they compared bolus versus
infusion and high dose versus low dose of furosemide. There
was no difference in the net fluid loss at 72 h in bolus versus
continuous infusion arms (p ¼ 0.89), but high dose group had
greater diuresis than low dose group (p ¼ 0.001). In DAD-HF
trial17 they compared high dose furosemide 20 mg/h contin-
uous infusion versus low dose dopamine 5 mg/kg/min þ low
dose furosemide 5 mg/h infusion for 8 h. The mean hourly
excreted urine volume was similar between the two groups
(272  149 ml, 278  186 ml; p ¼ 0.965).
In our study, the duration of hospital stay was shorter in
the bolus group (mean ¼ 5.03 days; p ¼ 0.023). This could be
because of rapid initial diuresis leading to early symptomatic
improvement and shorter hospital stay. However, other
studies showed different results. In DAD-HF trial17 length of
hospital stay were similar in the two groups (mean 5.3 versus
6.1 days; p¼ 0.2). In DOSE trial16 the length of hospital staywas
similar in bolus and infusion group (mean of 5 days; p ¼ 0.97).
Studies by Thomson et al10 and Patricia et al18 showed a
shorter hospital stay with continuous infusion. A retrospec-
tive analysis by Emad et al19 had a shorter hospital stay
(p¼ 0.015) with infusionþ dopamine group. These differences
could be due to differences in study design.
Our study showed no statistically significant difference
in serum sodium, serum potassium, blood urea and serum
creatinine levels at various time intervals between the three
groups (p > 0.05). In DAD-HF trial,17 the laboratory values at
24 h between the two groups were - serum sodium (mEq/l)
(138  4, 138  4; p ¼ 0.593), serum potassium (mEq/l)
(3.9  0.4, 4.2  0.5; p ¼ 0.027), urea (mg/dl) (62.5  23.4,
58.9  16.7; p ¼ 0.927) and serum creatinine (mg/dl)
(1.38  0.52, 1.25  0.33; p ¼ 0.679). This difference in serum
potassium level could be because of the difference in studydesign. In DOSE trial,16 there was no significant difference in
serum creatinine levels from baseline to 72 h between bolus
and infusion group (p ¼ 0.45). However, Emad et al19
observed improvement in serum creatinine (p ¼ 0.0001),
and an increase in eGFR 57.4  27.4 ml/min with
infusion þ dopamine as compared to boluses. This could be
due to the reno-protective effect.20 Ungar et al21 demon-
strated a progressive increase in effective renal plasma flow,
eGFR and reduction of renal vascular resistance starting
from a dopamine dose of 2 mg/kg/min, and peaking at 4 mg/
kg/min (þ75% and þ101% versus baseline, respectively).
Elkayam22 attributed the dilation of large conductance and
small resistance renal blood vessels as the cause for in-
crease in renal blood flow.
The number of emergency visits to the hospital for recur-
rent HFwithin the first month of discharge was not significant
among the three groups (p ¼ 0.673). We had two deaths in the
bolus and one in the infusion group during the one month
follow up. The study population is too small to derive differ-
ences in death outcomes. In DAD-HF trial,17 there was no
difference between the groups for all cause rehospitalisation
(p ¼ 0.254) and all cause mortality (p ¼ 1.000) at 60 days.5. Limitations
1. This was a single blinded, single center study with a small
sample size.
2. As patients admitted with ADHF were clinically unstable,
baseline weight and eGFR could not be determined. Hence
we used blood urea and serum creatinine as a measure to
see for worsening renal function.
3. We used a negative fluid balance as a proxy measure of
clinical benefit. We did not consider other end points like
relief of dyspnea and weight loss.6. Conclusion
All three modes of diuretic therapies can be practiced with no
difference in worsening of renal function and electrolyte
levels. Bolus dose administration with its rapid volume loss
and shorter hospital staymight be an attractive strategy in our
country with limited health resources. However, larger pop-
ulation studies are needed to further evaluate this strategy.Conflicts of interest
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